Sponsored
Joe Reynolds, Head of User Experience Services at Noble, breaks down what it really takes for pharmaceutical companies to move therapy from the clinic into the patient's home.
|Articles|March 20, 2023
PAP 2023: Corey Ford Discusses Experience in Tackling Reimbursement Challenges at Access PAP 2023
AmerisourceBergen exec explains how his experience in health policy analysis and data analytics helps him tackle patient access obstacles.
Advertisement
In an interview with Pharma Commerce Editor, Nicholas Saraceno, Corey Ford, VP of reimbursement & policy insight, AmerisourceBergen, desribes his experience in combating reimbursement challenges at Access PAP 2023.
Advertisement
Related to this article
As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
An FTC settlement moved one PBM aggregator onshore, but manufacturers still lack contract-level clarity on what affiliated fees actually buy.
Pharma pricing shifts beyond PBM rebates as Medicare and cash channels reshape launches, WAC cuts and access strategies.
In the final installment of his interview with Pharmaceutical Commerce, Cencora's Ameer Ali outlines how supply chain stakeholders should prepare systems, processes and trading partners for the shift to NDC-12.
In the final installment of his interview with Pharmaceutical Commerce, Cencora's Gregg Gorniak looks back at DSCSA's five-year evolution and where serialized data is creating value beyond compliance.
HDA's Kala Shankle unpacks the biggest open question on preemption and offers a two-step playbook for wholesalers and 3PLs preparing for national licensure.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How Rebate Timing Distorts a Pharmacy's 340B Books
2
EU Pharma Reform: Strategic Implications for US Drugmakers
3
White House Extends MFN Pricing to Every State Medicaid Program
4
Pharma Pulse: Behind the Scenes of LogiPharma USA 2026
5